Introduction {#s0001}
============

Approximately 140 million people live in plateau areas at high altitudes (\>2500 m) (Pratali et al. [@CIT0025]). The Qinghai-Tibetan Plateau, known as the 'Roof of the World', is the largest and highest plateau in the world, with an average altitude of \>4000 m above sea level (Yang et al. [@CIT0042]). Currently, more than ten million people ordinarily reside at Qinghai-Tibetan Plateau. In addition, increasing numbers of people who live in low altitude areas migrate to the plateau for travel or work. Acute exposure to high altitude may cause acute mountain sickness \[dizziness, nausea, palpitation, shortness of breath, high-altitude pulmonary edoema, high-altitude cerebral edoema and high-altitude pulmonary hypertension (HAPH)\] (Barry and Pollard [@CIT0003]; Beall et al. [@CIT0004]). HAPH is a severe health consequence of chronic exposure to hypobaric hypoxia, with a frequent occurrence of 15% in high-altitude regions (Leon-Velarde et al. [@CIT0019]). HAPH is characterised by increased pulmonary vascular resistance, pulmonary vasoconstriction and vascular remodelling of pulmonary arterioles (Beall et al. [@CIT0004]), and HAPH is the leading cause of death from altitude sickness (Hackett and Roach [@CIT0011]). Currently, there are no efficacious therapeutic treatments for HAPH. Therefore, it is important and necessary to develop novel medicines to improve treatments for HAPH-associated sicknesses.

*Salvia przewalskii* Maxim (Labiatae) (SPM) is mainly produced in the western regions of China (Gansu, Qinghai, and Tibet). The main pharmacological activities of SPM are similar to those of *Salvia miltiorrhiza* Bunge, which is a well-known traditional Chinese medicine with pharmacological functions that can be used to treat angina pectoris, stroke, atherosclerosis, myocardial infarction, liver fibrosis and hepatitis in clinical practice (Fei et al. [@CIT0010]; Yu et al. [@CIT0043]). Dripping pills of *S. miltiorrhiza* were approved for phase III clinical trials by the Food and Drug Administration (FDA) (Hao et al. [@CIT0012]; Jia et al. [@CIT0017]), while SPM has not been included in the 'Chinese Pharmacopoeia'. The pharmacological activity of SPM is not completely clear and urgently needs to be detected.

Here, we report the antihypoxia activity and mechanism of SPM. Proteins are key to the biological function. Proteomics has been increasingly widely used in traditional medicine research (Olson et al. [@CIT0023]; Ribon et al. [@CIT0027]). The combination of proteomics and bioinformatics analysis provides a new way to gain insight into the targets, mechanisms and effective components of natural herbs. This research aimed to study changes in specific protein expression levels or protein species in the lungs of high-altitude rats and SPM-treated hypoxia rats in response to high-altitude hypobaric hypoxia by using tandem mass tag (TMT)-based quantitative proteomics analysis. We hope to find potential target proteins to better understand SPM's antihypoxia mechanism.

Materials and methods {#s0002}
=====================

Preparation of SPM suspension {#s0003}
-----------------------------

SPM roots were collected from Minhe (Qinghai Province, China), in October 2018, and identified by DD (one of the authors). The voucher specimen (20181011) was deposited in People's Hospital of Qinghai Province. The SPM was cleaned, dried, pulverised, and extracted with 70% ethanol with ultrasound (power, 180 W; frequency, 40 kHz) for 50 min. The extract solution was centrifuged, dried and ground to obtain the extract powder. The desired concentration of SPM suspension was prepared by dissolving the extract powder with deionised water.

Detection of the major active components of SPM by HPLC {#s0004}
-------------------------------------------------------

The SPM extract powder was dissolved with 500 µL of 80% methanol and then filtered through a 0.22 µm nylon mesh into sample vials. The test sample and mixed standard sample analyses were performed with an Agilent 1290 Infinity LC system coupled to an ultraviolet-visible (UV-vis) detector (Agilent, USA). Chromatographic separation of test samples and mixed standard samples was performed on a SunFire C-18 threaded column (4.6 × 250 mm, 5.0 μm, Waters, USA) maintained at 26 °C. The mobile phase consisted of solvent A (0.1% formic acid in acetonitrile, v/v) and B (0.1% formic acid in water, v/v). The post time was set to 3 min for equilibration. The SPM detection method was further validated by inspecting the linear range, precision, repeatability, and recovery rate according to FDA guidance for the validation of bioanalytical methods.

Animal experiments {#s0005}
------------------

Thirty male SPF-grade Sprague-Dawley (SD) rats (7 weeks old, weighing 160--180 g) were purchased from the Experimental Animal Centre of Xi'an Jiaotong University (license key: SCXK (Shaanxi) 2017-003). All rats were housed in facilities with a controlled relative humidity (45--65%), temperature (22 ± 2 °C) and a 12 h light/dark cycle. Feed and drinking water were supplied to the rats *ad libitum*. All rats were randomly assigned to three groups (*n* = 10): (I) normal group (the rats were raised in Xining; altitude, approximately 2260 m); (II) hypoxia group (the rats were raised in Maduo; altitude, approximately 4260 m); (III) hypoxia + SPM groups (the rats were administered a dose of SPM (1.0 g/kg body weight every day) by gavage and raised in Maduo; altitude, approximately 4260 m). The experiment persisted for 4 weeks.

At the end of the experiments, all animals were anaesthetised with phenobarbital (intraperitoneal injection, 30 mg/kg), and the mean pulmonary arterial pressure (mPAP) was detected by a pulmonary artery pressure recorder. All animals were sacrificed under anaesthesia, and the lungs were immediately carefully isolated. Some tissues were fixed with 10% formalin, dehydrated with gradient alcohol, embedded in paraffin, sliced with a microtome and stained with haematoxylin and eosin (H&E) for pathological observations by light microscopy. Some lung tissues were frozen in liquid nitrogen and then transferred and stored at −80 °C until analysis. Some lung tissues were homogenised with a tissue homogeniser at 4 °C, and then the homogenate was centrifuged at 10,000 rpm for 10 min at 4 °C. The supernatant was transferred to a new tube and stored at −80 °C until analysis. The concentrations of malondialdehyde (MDA) and superoxide dismutase (SOD) were detected using commercial kits according to the manufacturer's protocols (the two kits were purchased from Nanjing Jiancheng Bioengineering Institute, Nanjing, China).

Protein extraction {#s0006}
------------------

Six samples of lung tissues from the hypoxia + SPM and hypoxia groups were processed individually, and each group had three rats. Each lung tissue was treated with SDT (4% SDS, 100 mM Tris-HCl, pH 7.6) and transferred to a Lysing Matrix A tube, and an MP homogeniser was used to crush the sample (24 × 2, 6.0 M/S, 60 s, twice). After ultrasound, the samples were incubated in a boiling water bath for 10 min. Then, the samples were centrifuged at 14,000 *g* for 15 min. Finally, the supernatant was collected and filtered using a 0.22 μm centrifuge tube filter. The protein concentration was quantified by a BCA kit (Beyotime, Shanghai, China) (Zhu et al. [@CIT0044]). The samples were packed and stored at −20 °C.

SDS-PAGE {#s0007}
========

A 6X loading buffer solution (Beyotime, Shanghai, China) was added to each protein sample (50 μg), and the samples were processed in a boiling water bath for 5 min. Then, the samples were loaded onto 12% SDS-PAGE and subjected to electrophoresis at 250 V for 40 min. The gels were stained with a solution containing Coomassie brilliant blue.

FASP enzymolysis {#s0008}
----------------

For digestion, 5 mM dithiothreitol (DTT, 43819-5 G, Sigma) was added to the protein solution (200 μg), and the mixture was incubated for 5 min in boiling water. The samples were then naturally cooled to room temperature. Next, 200 μL of UA buffer (8 M urea, 150 mM Tris-HCl, pH 8.5) was used to remove the DTT and detergent components by ultrafiltration (30 kD), followed by centrifugation at 12,500 *g* for 25 min (repeated this step twice). Subsequently, 100 μL of iodoacetamide (IAA) buffer was added to the concentrate, followed by centrifugation at 12,500 *g* for 25 min. Then, 100 μL of UA buffer was added to the resulting concentrate, the sample was centrifuged at 12,500 *g* for 15 min, and this step was repeated two additional times. Afterwards, 100 μL of 0.1 M triethylammonium bicarbonate (TEAB, SE252676/90114, Thermo) was added, followed by centrifugation at 12,500 *g* for 15 min, and this step was repeated two times. Finally, the protein suspensions were digested for 16--18 h at 37 °C with 40 μL of trypsin buffer (4 μg trypsin in 40 μL of 0.1 M TEAB). Finally, the sample was centrifuged at 12,500 *g* for 15 min, and the filtrate was collected (Wiśniewski et al. [@CIT0041]; Wang et al. [@CIT0036]).

TMT labelling, HPLC fractionation and LC − MS/MS {#s0009}
------------------------------------------------

After trypsin digestion, 100 μg of peptide was taken from each sample and labelled according to TMT (Tandem Mass Tag) 6 plex Isobaric Mass Tag Labelling kit protocol (Thermo Fisher Scientific, Torrance, CA, USA). The samples were labelled as follows: A1:126, A2:127, A3:128, B1:129, B2:130, and B3:131. The labelled samples were subsequently fractionated by high pH reverse-phase high-performance liquid chromatography (Agilent 1260 infinity II HPLC). The samples were added to a C18-reversed phase column (Thermo Fisher Scientific) in buffer A (10 mM HCOONH~4~, 5% ACN, pH 10.0) and then separated with buffer B (10 mM HCOONH~4~, 85% ACN, pH 10.0). The peptides were separated using a flow rate of 300 nL/min. The chromatographic column was balanced with buffer A, the sample was loaded using an automatic sampler, and the flow rate was 1 mL/min. The gradient profile was 0--7% B from 0 min to 65 min, 7--40% B from 65 min to 70 min and 10--100% B from 70 min to 85 min. The fractions were combined and then vacuum-dried. The dried samples were subsequently reconstituted and evaluated by LC-MS/MS (Thermo Fisher Scientific), and the detailed procedures of the LC-MS/MS methodology were performed as previously described (Wang et al. [@CIT0036]; [@CIT0037]). An MS^1^ survey scan of 350--1800 *m/z* at a resolution of 70,000 was collected with an AGC target of 3.0 × 106 and maximum injection time of 50 millisecond (ms). Following fragmentation, the MS^2^ precursor population was selected using the SPS waveform (10 notches) and then fragmented by HCD (2 *m/z* isolation window, maximum injection time of 45 ms, resolution of 35,000, microscans of 1, normalised collision energy of 30 eV).

MS/MS data analysis and bioinformatics analysis {#s0010}
-----------------------------------------------

The raw MS/MS data were input into the Mascot 2.6 and Proteome Discoverer 2.1 databases with a false discovery rate (FDR) \< 0.01 at the protein and peptide levels. The search parameters included 6 plex TMT, allowing 2 missing cleavages by cleavage enzyme trypsin, fixed modification (carbamidomethyl) and variable modification (oxidation, protein N-term acetylation). The mass error was set to 10 ppm in the first search, and the fragment ions of mass tolerance were set to 0.05 Da. All identified proteins had ≥2 peptides with ≥1 unique peptide, and only the proteins at *p* \< 0.05 were considered to be accurately quantified. For the comparison between the hypoxia + SPM and hypoxia groups, a protein with a fold change of \> ± 1.2 and a *p*-value of \<0.05 was regarded as a differentially expressed protein. The Blast2GO database provided Gene Ontology (GO) annotation data. The Kyoto Encyclopaedia of Genes and Genomes (KEGG) database was used to perform pathway enrichment analysis. Protein-protein interaction (PPI) networks were identified and visualised with the IntAct (<http://www.ebi.ac.uk/intact/main.xhtml>) database and Cytoscape software (version 3.2.1), respectively.

RNA extraction and real-time quantitative PCR {#s0011}
---------------------------------------------

The total mRNA was isolated from the lung using the Trizol reagent (TaKaRa, Dalian, China) following the manufacturer's protocol. Complementary DNA synthesis was performed using a HiScript 1st Strand cDNA Synthesis Kit (TaKaRa, Dalian, China). Real-time quantitative PCR (RT-qPCR) was used to detect hypoxia-inducible factor-1α (HIF-1α) with the ABI-7900HT system (Applied Biosystems) (*n* = 10). The Mmp8, Fabp1, Bmi1, Aldob, Adh7 and Khk genes were also evaluated by RT-qPCR to validate the proteomics results (*n* = 6). The relative expression of genes was calculated using the 2^−△△Ct^ method. The details of the primers used are listed in [Table 1](#t0001){ref-type="table"}.

###### 

Target gene information and primers for real-time PCR.

  Target gene   Primer sequence (5′→3′)   Amplicon size (bp)          
  ------------- ------------------------- --------------------------- -----
  HIF-1α        CCAGATTCAAGATCAGCCAGCA    GCTGTCCACATCAAAGCAGTACTCA   162
  Mmp8          CCACTTACCAAGCAATCAG       GAGTTAGCAAGAAATCACC         179
  Fabp1         TTCTCCGGCAAGTACCAAG       TCTCCAGTTCGCACTCCTC         211
  Bmi1          TTAGTTCCAGGGCTTTTCA       ACCTCCTCCTTTGGCTTCT         224
  Aldob         TTGCCAATGGGAAGGGTAT       GAGCGTCTCATGGAAAAGG         182
  Adh7          TATCACCCdTGAAATCCCG       TaCCACTCGCTGcTAATGC         122
  Khk           GATTTATTAACCGACATCTG      CTCGATCTACCTTGACATC         230
  Gapdh         TTCAACGGCACAGTCAAGG       CTCAGCACCAGCATCACC          114

Statistical analysis {#s0012}
====================

Statistical analysis was performed using GraphPad Prism 5.0 software (GraphPad, CA, USA). The comparison of means of three groups was carried out using one-way analysis of variance (ANOVA), and differences between two groups were determined by unpaired two-tailed Student's *t*-test. For volcano plot, histogram and clustering analysis, the proteomics data were log transformed and normalised when appropriate. For enrichment analysis, Fisher's exact test was applied. *p*-Values less than 0.05 were considered statistically significant (\**p*-value \<0.05; \*\**p*-value \<0.01; and \*\*\**p*-value \<0.001; ns: not significant, *p*-value \>0.05).

Results {#s0013}
=======

The major components of SPM and its significant antihypoxia effects {#s0014}
-------------------------------------------------------------------

HPLC analysis showed that the major components and contents of SPM extract were rosmarinic acid (4.334%) and salvianolic acid B (2.526%) ([Figure 1(A,B)](#F0001){ref-type="fig"}). The hypoxia experiments were performed at an altitude of 4260 m. The hypoxia rats showed poor diet, polypnea and less active, but the hypoxia + SPM rats reversed the hypoxia phenotype. And the results showed that mPAP was significantly increased in the hypoxia groups compared with the control group (*p* \< 0.001) ([Figure 1(C)](#F0001){ref-type="fig"}). The number of alveoli and the alveolar space were reduced, the structure was disordered, red blood cells leaked, the alveolar septum was thickened, the capillary was seriously congested and the wall of the tubes was thickened in the lung in the hypoxia groups ([Figure 1(D)](#F0001){ref-type="fig"}). HIF-1α activation is well known to be induced by hypoxia, and HIF-1α is a marker of hypoxia (Soeda et al. [@CIT0032]). In our study, the level of HIF-1α mRNA was significantly increased in the rats in the hypoxia group compared with those in the control groups (*p* \< 0.001) as detected by RT-qPCR ([Figure 1(E)](#F0001){ref-type="fig"}). All of these results indicated that feeding rats for 4 weeks at an altitude of 4260 m led to HAPH pathology and lesions. However, as indicated in [Figure 1(C--E)](#F0001){ref-type="fig"}, compared with hypoxia, SPM markedly decreased mPAP and HIF-1α (*p* \< 0.001 or .01); these results were further confirmed by pathology examination. As shown in [Figure 1(D)](#F0001){ref-type="fig"}, the lung pathology in the hypoxia + SPM group was clearly improved and showed basically normal organisational form and structure. These results indicated that SPM has clear antihypoxia effects.

![SPM showed significant antihypoxia effects. (A) HPLC chromatogram of mixed standard solutions. (B) HPLC chromatogram of SPM extract. (C) Oral administration of SPM for 4 weeks significantly decreased the levels of mPAP compared with Hypoxia groups (*n* = 10). (D) H&E staining of lung in different groups (×200) (*n* = 10). (E) The effects of SPM on HIF-1α mRNA expressions in lung by RT-qPCR (*n* = 10). \*\*\**p* \< .001, \*\**p* \< .01, ns: not significant, *p* \> .05.](IPHB_A_1762668_F0001_C){#F0001}

Data analysis and protein identification {#s0015}
----------------------------------------

To investigate the antihypoxia mechanisms of SPM, we analysed the protein expression profile of the lung in the hypoxia + SPM and hypoxia groups after the comparative proteomics experiment. In this study, proteomic data were acquired by TMT-based LC-MS/MS analysis. As a result, a total of 44,919 peptides derived from 6658 proteins were identified through a regular search of the proteome database with Mascot 2.6 and Proteome Discoverer 2.1 software. Among the identified proteins, 28 proteins were differentially altered, with ratios \>1.2 or \<0.83, and they were used to create a protein list that was further filtered through statistical significance criteria (*p*-value \< 0.05). A total of 8 upregulated and 20 downregulated proteins were identified in the hypoxia + SPM group compared with the hypoxia group ([Table 2](#t0002){ref-type="table"}).

###### 

Differentially expressed proteins with increased or decreased expression in lung from hypoxia + SPM group and hypoxia group.

  Accession no.   Gene name   Protein description                      Fold change   *p* Value
  --------------- ----------- ---------------------------------------- ------------- -----------
  Q62715          Defa        Neutrophil antibiotic peptide NP-2       1.48          .048
  D4AAP6          Mn1         Transcriptional regulator                1.40          .028
  Q5RJS2          Rhoj        Ras homologue family member J            1.28          .005
  G3V8A4          Mtr         Methyltransferase                        1.27          .026
  P35444          Comp        Cartilage oligomeric matrix protein      1.27          .038
  G3V7D0          Mmp8        Matrix metalloproteinase                 1.26          .027
  P10959          Ces1c       Carboxylesterase 1C                      1.23          .023
  F1LVC4          Tigd2       Tigger transposable element-derived 2    1.20          .029
  D3ZJA8          Cnep1r1     CTD nuclear envelope phosphatase 1       0.83          .025
  Q8VH49          Higd1a      HIG1 domain family member 1A             0.83          .038
  G3V7J9          Adh7        Alcohol dehydrogenase class 4            0.83          .015
  D3ZY68          Gatc        Glutamyl-tRNA (Gln) amidotransferase     0.82          .029
  Q4V8J1          Ppip5k2     Uncharacterized protein                  0.82          .012
  Q3B8N9          Bphl        Biphenyl hydrolase-like                  0.82          .015
  A0A0G2JSU8      Cyp2d1      Cytochrome P450 2D1                      0.81          .014
  B4F7B6          Bmi1        BMI1 proto-oncogene                      0.81          .009
  B2RZ23          Cenpa       Centromere protein A                     0.80          .022
  P84586          Rbmxrtl     RNA-binding motif protein                0.80          .038
  Q02974          Khk         Ketohexokinase                           0.80          .008
  Q811A3          Plod2       Procollagen-lysine                       0.80          .010
  Q4G064          Coq5        Methylase                                0.80          .016
  F1LN38          Selenow     Selenoprotein W                          0.79          .019
  F1M7P4          Prph        Peripherin                               0.79          .014
  Q5U3Y7          Tmem97      Sigma intracellular receptor 2           0.79          .027
  D4A6W9          Capsl       Calcyphosine-like                        0.76          .028
  A0A0A1FZ38      ND3         NADH-ubiquinone oxidoreductase chain 3   0.75          .018
  P02692          Fabp1       Fatty acid-binding protein               0.52          .042
  P00884          Aldob       Fructose-bisphosphate aldolase B         0.49          .021

The separation of SDS-PAGE strip for each sample was clear ([Figure 2(A)](#F0002){ref-type="fig"}). The volcano plot in [Figure 2(B)](#F0002){ref-type="fig"} also presents the differential expression of proteins. For all 28 differentially expressed proteins, the frequency distribution of the log2-transformed A/B ratios in each group fit a normal distribution ([Figure 2(C)](#F0002){ref-type="fig"}). The hierarchical clustering heat map in [Figure 2(D)](#F0002){ref-type="fig"} shows the differentially expressed proteins in each group and the functional clustering analysis of different proteins. Hierarchical clustering indicated that there were two main branches, i.e., the hypoxia + SPM (A) and hypoxia (B) groups. From these data, it was clear that the samples from the hypoxia + SPM and hypoxia groups were clustered into their respective categories.

![Characteristics of the identified proteins in hypoxia + SPM group and hypoxia group. (A) The result of SDS-PAGE. (B) The differentially expressed proteins are visualised by volcano plot. A protein with a fold change \>1.2 or \<0.83 and *p* \< .05 is regarded as an up- or downregulated protein, which is coloured in red. The identified proteins with no significant changes are plotted in grey. Proteins with up- or downregulated abundance are shown on the right-hand side and left-hand side of the figure, respectively. (C) The quantitative ratio histogram of quantitative proteins. (D) Hierarchical clustering heat map of the 28 differentially expressed proteins. The colour of blue and red represent the up- and downregulated proteins, respectively. A1, A2, and A3, 3 replicates of hypoxia + SPM; B1, B2, and B3, 3 replicates of hypoxia. A/B represents hypoxia + SPM/hypoxia group.](IPHB_A_1762668_F0002_C){#F0002}

Annotation analysis of the differentially expressed proteins {#s0016}
------------------------------------------------------------

We submitted all differentially expressed proteins to GO enrichment and KEGG pathway annotation. The annotated proteins were strongly enriched in the GO categories of fructose catabolic process, response to fructose, DNA methylation, inositol metabolic process, rough endoplasmic reticulum membrane, antioxidant activity, etc. ([Figure 3(A)](#F0003){ref-type="fig"}). To gain insights into the functional differences between the lung proteomes of the hypoxia + SPM group and those of the hypoxia group, the dysregulated proteins were mainly mapped to KEGG pathways. The enriched KEGG pathways were fructose and mannose metabolism, glycolysis/gluconeogenesis, biosynthesis of secondary metabolites, ubiquinone and other terpenoid-quinone biosynthesis and biosynthesis of amino acids ([Figure 3(B)](#F0003){ref-type="fig"}). Notably, the most dysregulated proteins were related to fructose catabolism or metabolism, which implied that some significantly altered proteins/enzymes in the lung under high-altitude hypobaric hypoxia conditions were generally related to fructose catabolism or metabolism. The protein-protein interaction (PPI) network analysis with the IntAct database (<http://www.ebi.ac.uk/intact/main.xhtml>) and CytoScape software (version number: 3.2.1) obviously revealed that one crosstalk signalling cluster was related to fructose catabolism or metabolism ([Figure 3(C)](#F0003){ref-type="fig"}).

![Enrichment analysis of the differentially expressed proteins. (A) GO term enrichment analysis of the differentially expressed proteins in cellular component, molecular function, and biological process. (B) Differentially expressed proteins corresponding to pathways analysed by KEGG pathway enrichment. (C) Analysis of protein − protein interaction network of the differentially expressed proteins. IntAct database and Cytoscape software were used to annotate and visualise functional interactions of all the 28 differentially expressed proteins.](IPHB_A_1762668_F0003_C){#F0003}

Validation of proteomics results {#s0017}
--------------------------------

Six proteins, i.e., Mmp8, Fabp1, Bmi1, Aldob, Adh7, and Khk, were chosen to validate the TMT-based proteomics quantitative results using RT-qPCR according to the following selection criteria: upregulation or downregulation in all the replicated analyses, potential functional significance in high-altitude hypobaric hypoxia and different functional categories or pathways. [Figure 4](#F0004){ref-type="fig"} displays the validation results. In line with the proteomic results, Mmp8 levels were increased in the hypoxia + SPM group compared to the hypoxia group (*p* \< 0.01) ([Figure 4(A)](#F0004){ref-type="fig"}), whereas Fabp1, Bmi1, Aldob, Adh7 and Khk were notably downregulated (*p* \< 0.01 or 0.001) ([Figure 4(B--F)](#F0004){ref-type="fig"}). Some differentially expressed proteins were strongly enriched in the GO categories of antioxidant activity, so the SOD and MDA related to antioxidant activity was also tested in the lung. The results indicated that the SOD content was significantly increased (*p* \< 0.01) ([Figure 4(G)](#F0004){ref-type="fig"}) and that the MDA level was significantly decreased in the hypoxia + SPM group compared with the hypoxia group (*p* \< 0.05) ([Figure 4(H)](#F0004){ref-type="fig"}).

![Validations of differentially changed proteins by RT-qPCR, and the levels of SOD and MDA were detected using colorimetric method. (A) Mmp8 (*n* = 6), (B) Fabp1 (*n* = 6), (C) Bmi1 (*n* = 6), (D) Aldob (*n* = 6), (E) Adh7 (*n* = 6), (F) Khk (*n* = 6), (G) SOD (*n* = 10), and (H) MDA (*n* = 10). Data represent the mean ± SD. \**p* \< .05, \*\**p* \< .01, \*\*\**p* \< .001.](IPHB_A_1762668_F0004_C){#F0004}

Discussion {#s0018}
==========

Medicinal plants commonly contain many bioactive constituents that have multiple biological activities. Rosmarinic acid is an abundant phenolic ester and has reported a range of biological effects of anti-diabetes (Ngo et al. [@CIT0022]), anti-inflammatory, and anticancer activities (Amoah et al. [@CIT0001]). Salvianolic acid B is one of abundant molecule isolated from the aqueous fraction of *S. miltiorrhiza* and has been shown to exert various antioxidative, anti-inflammatory (Chen et al. [@CIT0006]), antitumour (Wang et al. [@CIT0038]; Sha et al. [@CIT0031]), and anti-emphysema (Dhapare and Sakagami [@CIT0008]) effects. In the present study, we demonstrated that extracts from SPM contain two main components, rosmarinic acid and salvianolic acid B. The bioactivity of SPM extract may be associated with the components.

Compared with low altitude regions, high altitude regions have significantly decreased atmospheric pressure and partial oxygen pressure (Jacobsen [@CIT0013]). HAPH is a severe health consequence of chronic exposure to hypoxia with a prevalence of up to 15% (Leon-Velarde et al. [@CIT0019]). Herbal medicines play an important role in primary health care in many low- and middle-income countries. The main pharmacological activities of SPM are treating angina pectoris, stroke, atherosclerosis, myocardial infarction, liver fibrosis and hepatitis (Fei et al. [@CIT0010]; Yu et al. [@CIT0043]). In the present study, we demonstrated that SPM exhibits significant antihypoxia effects. To clarify the antihypoxia mechanism of SPM, we conducted TMT-based comparative proteomics analysis to analyse the differences in the lung proteomics profiles between the hypoxia + SPM groups and the hypoxia groups. In total, we identified 28 significantly altered (20 downregulated and 8 upregulated) proteins. Rhoj belongs to the super-family of small G proteins. Rhoj is abundantly expressed in vascular endothelial cells and has been shown to participate in a number of endothelial-cell related pathophysiological processes including angiogenesis and hypoxia (Kaur et al. [@CIT0015]; Kim et al. [@CIT0016]; Wilson et al. [@CIT0039]; Liu et al. [@CIT0020]). The blocking of endothelial Rhoj has been proposed as a novel anti-angiogenesis approach (Kim et al. [@CIT0016]). MMP activity is crucial in the healthy lung for physiological processes (Dejonckheere et al. [@CIT0007]). Lung disorders are associated with a high degree of oxidative stress, and MMP8 is highly sensitive to activation by reactive oxygen species (ROS) (Saari et al. [@CIT0029]). MMP8 plays an anti-inflammatory role in both acute and chronic lung disorders through modulating numerous inflammatory mediators and clearing inflammatory cells from the site of infection (Dejonckheere et al. [@CIT0007]). SPM can promote angiogenesis and exert an anti-inflammatory role through upregulating Rhoj and Mmp8 expression. And according to bioinformatics analysis, several annotated differentially expressed proteins were enriched in fructose catabolism or metabolism, antioxidative stress, and glycolysis/gluconeogenesis. These proteins are involved in the antihypoxia mechanism of SPM under the influence of hypobaric hypoxia.

Expression of antioxidant proteins {#s0019}
----------------------------------

The high altitude exposure results under decreased partial pressure of oxygen and enhanced formation of ROS through mitochondrial electron transport chains, xanthine oxidase/reductase, NADPH oxidase, nitric oxide synthase enzymes, and inflammatory process (Dosek et al. [@CIT0009]; Winterbourn [@CIT0040]; Arya et al. [@CIT0002]), which cause oxidative stress (Jayalakshmi et al. [@CIT0014]; Maiti et al. [@CIT0021]). This hypoxia-induced redox imbalance is a primary factor for lung pathological processes, such as increased pulmonary artery pressure, vascular proliferation, edoema, right heart failure and inflammation (Rosanna and Salvatore [@CIT0028]; Sylvester et al. [@CIT0033]; Tuder and Petrache [@CIT0034]). Oxidative stress-related proteins are known to be controlled in redox regulation. Exposure to high altitude appears to decrease the activity and cellular defence systems of antioxidant enzymes (Ramanathan et al. [@CIT0026]). A previous study reported that proteins involved in oxidoreductase activity were upregulated under hypoxia (Bousquet et al. [@CIT0005]). In this study, SPM showed clear antihypoxia effects with decreased mPAP and HIF-1α mRNA and improved HAPH pathology. SPM reduced oxidoreductase activity by downregulating the expression of Adh7, Cyp2d1, Plod2, Selenow, ND3 and Fabp1 according to GO annotation; meanwhile, SPM could effectively inhibit oxidative damage by enhancing antioxidant (SOD) levels and reducing oxidative stress (MDA) levels. Our results suggest that SPM can confer protection against hypoxia-induced oxidative stress by inhibiting oxidoreduction systems.

Expression of proteins associated with fructose metabolism {#s0020}
----------------------------------------------------------

Differential proteomic results showed the downregulation of Khk and Aldob, proteins related to fructose metabolism. Fructose is a natural monosaccharide broadly used in modern society. Fructose is absorbed *via* two major facilitative glucose transporters: GLUT5 and GLUT2 (Pan and Kong [@CIT0024]). Fructose metabolism requires the coordinated action of 2 enzymes, ketohexokinase (Khk), which phosphorylates fructose to form fructose 1-phosphate (Fru1-P), and aldolase B, which splits Fru1-P into dihydroxyacetone phosphate and glyceraldehydes (Lanaspa et al. [@CIT0018]), thereby producing substrates for fatty acid synthesis. Fructose bypasses glycolysis, and fructose is utilised much faster than glucose in *de novo* lipogenesis (Samuel [@CIT0030]); thus, the excessive intake of fructose is closely associated with metabolic diseases such as diabetes and obesity (Walker and Goran [@CIT0035]). Therefore, the repression of fructose-induced fatty liver is a key strategy for the prevention of these metabolic diseases. In this report, through the use of comparative proteomics, we demonstrate that SPM inhibited fructose metabolism *via* the downregulation of Khk and Aldob protein expression to prevent the lung injury associated with hypobaric hypoxia.

Conclusions {#s0021}
===========

This study demonstrated that *Salvia przewalskii* has an antihypoxia effect on hypobaric hypoxia at high altitude by increasing antioxidant capacity through the inhibition of oxidoreduction systems and by inhibiting fructose metabolism through the downregulation of the Khk and Aldob proteins.
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The proteomics data has been deposited at iProX database (IPX0001910000). The raw data of the 6658 protein (including the detailed gene name, molecular weight, score, coverage, peptides, unique peptides, GO annotation, KEGG pathway, enrichment analysis, fold changes, *p* value) is represented in [Supplementary 1](https://doi.org/10.1080/13880209.2020.1762668).

[^1]: Supplemental data for this article can be accessed [here](https://doi.org/10.1080/13880209.2020.1762668).
